During the past decade, North Georgia Rheumatology Group conducted 15 clinical trials. In the 10-year time frame, 15 clinical trials started and 13 clinical trials were completed, i.e. on average, 86.7% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 8 clinical trials were completed. i.e. 160% of trials that started reached the finish line.

Out of the total clinical trials conducted in "North Georgia Rheumatology Group" #1 sponsor was "Bristol-Myers Squibb" with 4 trials, followed by "Eli Lilly and Company" with 3 trials sponsored, "Gilead Sciences" with 2 trials sponsored, "Hoffmann-La Roche" with 2 trials sponsored and "Pfizer's Upjohn has merged with Mylan to form Viatris Inc." with 2 trials sponsored. Other sponsors include 3 different institutions and companies that sponsored additional 13 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "North Georgia Rheumatology Group" #1 collaborator was "Galapagos NV" with 2 trials as a collaborator, "Incyte Corporation" with 2 trials as a collaborator, "Biogen" with 1 trials as a collaborator, "Ono Pharmaceutical Co. Ltd" with 1 trials as a collaborator and "Oregon Health and Science University" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "North Georgia Rheumatology Group" are "Rheumatoid Arthritis" (5 trials), "Systemic Lupus Erythematosus" (5 trials), "Lupus Erythematosus, Systemic" (3 trials), "Psoriatic Arthritis" (2 trials) and "Ankylosing Spondylitis" (1 trials). Many other conditions were trialed in "North Georgia Rheumatology Group" in a lesser frequency.

Most popular intervention types in "North Georgia Rheumatology Group" are "Drug" (19 trials), "Other" (5 trials) and "Biological" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (9 trials), "BMS-986142" (2 trials), "Baricitinib" (2 trials), "Filgotinib" (2 trials) and "Abatacept" (1 trials). Other intervention names were less common.

The vast majority of trials in "North Georgia Rheumatology Group" are 21 trials for "All" genders.

Currently, there are NaN active trials in "North Georgia Rheumatology Group". undefined are not yet recruiting, 1 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 16 completed trials in North Georgia Rheumatology Group, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in North Georgia Rheumatology Group, 2 "Phase 1" clinical trials were conducted, 8 "Phase 2" clinical trials and 6 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 4 trials, and there were also 0 trials that are defined as “Not Applicable".